Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Public ClinicalTrials.gov record NCT01450761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Study identification
- NCT ID
- NCT01450761
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,351 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Biological
- Placebo matching Ipilimumab Biological
- Etoposide Drug
- Cisplatin Drug
- Carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2011
- Primary completion
- Mar 18, 2015
- Completion
- May 16, 2017
- Last update posted
- Jul 7, 2020
2011 – 2017
United States locations
- U.S. sites
- 42
- U.S. states
- 22
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Sutter Medical Center | Auburn | California | 95602 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92093 | — |
| University Of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists S. | Fort Myers | Florida | 33916 | — |
| Cancer Specialists, LLC | Jacksonville | Florida | 32256 | — |
| Lake City Cancer Care | Lake City | Florida | 32024 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Medical Oncology, LLC | Augusta | Georgia | 30901 | — |
| Quincy Medical Group | Quincy | Illinois | 62301 | — |
| Presence Medical Group Hematology Oncology | Skokie | Illinois | 60077 | — |
| SIU School Of Medicine | Springfield | Illinois | 62794-9678 | — |
| St. Francis Medical Group Oncology And Hematology Specialist | Indianapolis | Indiana | 46237 | — |
| Cancer Center Of Kansas | Wichita | Kansas | 67214 | — |
| Ashland Bellefonte Cancer Center | Ashland | Kentucky | 41101 | — |
| University Of Kentucky | Lexington | Kentucky | 40536-0093 | — |
| Montgomery Cancer Center | Mount Sterling | Kentucky | 40353 | — |
| St Joseph Mercy Hospital | Ypsilanti | Michigan | 48197 | — |
| St. Luke'S Cancer Institute | Kansas City | Missouri | 64111 | — |
| Southeast Nebraska Hematology & Oncology Consultants, P.C. | Lincoln | Nebraska | 68510 | — |
| Regional Cancer Care Associates, LLC/Cherry Hill Division | Cherry Hill | New Jersey | 08003 | — |
| Memorial Sloan Kettering Nassau | New York | New York | 10065 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oncology Hematology Care, Incorporated | Cincinnati | Ohio | 45242 | — |
| University Hospitals | Cleveland | Ohio | 44106 | — |
| Signal Point Clinical Research Center, Llc | Middletown | Ohio | 45042 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa | Oklahoma | 74104 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Kaiser Permanente | Portland | Oregon | 97227 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Associated in Oncology and Hematology | Chattanooga | Tennessee | 37421 | — |
| The Jones Clinic, PC | Germantown | Tennessee | 38138 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Henry-Joyce Cancer Center | Nashville | Tennessee | 37232 | — |
| University Of Texas, M. D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Research And Treatment Center | Lubbock | Texas | 79410 | — |
| Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
| Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 183 non-U.S. sites.
Recently updated Small Cell Lung Carcinoma trials
Other public records listing Small Cell Lung Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT04199741: PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 Recruiting
- NCT05419076: A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain Recruiting
- NCT04938817: Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) Recruiting
- NCT07006727: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors Recruiting
- NCT05882058: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Recruiting
- NCT06586957: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01450761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2020 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01450761 live on ClinicalTrials.gov.